HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takayuki Sugiura Selected Research

glyceryl 2-arachidonate (2-arachidonoylglycerol)

12/2006Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice.
5/2006Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol.
5/2005Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear.
2/2005Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells.
12/2004New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation.
11/20042-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils.
4/20042-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takayuki Sugiura Research Topics

Disease

7Inflammation (Inflammations)
06/2012 - 11/2004
5Leukemia
09/2009 - 04/2004
3Neoplasms (Cancer)
09/2009 - 02/2005
2Dermatitis
06/2012 - 01/2012
2Neuroblastoma
07/2010 - 06/2002
2Osteoporosis
09/2009 - 01/2008
2Hypereosinophilic Syndrome (Loeffler Endocarditis)
01/2006 - 11/2004
1Infections
10/2014
1Edema (Dropsy)
06/2012
1Disease Progression
01/2012
1Hypersensitivity (Allergy)
01/2012
1Bronchitis
01/2012
1Ischemia
10/2009
1Psoriasis (Pustulosis Palmaris et Plantaris)
01/2008
1Autoimmune Diseases (Autoimmune Disease)
01/2008
1Secondary Hyperparathyroidism
01/2008
1Contact Dermatitis (Eczema, Contact)
12/2006
1Glioma (Gliomas)
06/2002

Drug/Important Bio-Agent (IBA)

7LigandsIBA
06/2012 - 11/2004
7glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA
12/2006 - 04/2004
5CannabinoidsIBA
06/2012 - 06/2002
5CB2 Cannabinoid ReceptorIBA
12/2006 - 11/2004
3Cannabinoid Receptors (Cannabinoid Receptor)IBA
12/2006 - 11/2004
2OxazoloneIBA
06/2012 - 12/2006
2OvalbuminIBA
06/2012 - 01/2012
2Calcitriol Receptors (Calcitriol Receptor)IBA
09/2009 - 01/2008
2Biological ProductsIBA
09/2009 - 06/2002
2SR 144528IBA
12/2006 - 12/2004
1SphingomyelinsIBA
10/2014
1LipidsIBA
10/2014
1EnzymesIBA
10/2014
1Glycerol (Glycerine)FDA LinkGeneric
01/2012
1Arachidonic Acid (Vitamin F)IBA
07/2010
1LysophospholipidsIBA
10/2009
1OsteocalcinIBA
09/2009
1Cannabinoid Receptor AgonistsIBA
05/2006
1(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA
05/2006
1EndocannabinoidsIBA
12/2004
1ChemokinesIBA
04/2004
1CB1 Cannabinoid Receptor (CB1 Receptor)IBA
06/2002
12-arachidonoyl-sn-glycero-3-phosphateIBA
06/2002
1Lysophosphatidic Acid ReceptorsIBA
06/2002